The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Open accessAbstract
The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy. In the last few years, immune‐checkpoint inhibitors (ICIs) have revolutionized cancer therapy and have gained an increased interest in the treatment of HCC. In 2020, the combination of atezolizumab (anti‐programmed death‐ligand 1) and bevacizumab (anti–vascular endothelial growth factor) improved overall survival over sorafenib, resulting in Food and Drug Administration (FDA) approval as a first‐line treatment for patients with advanced HCC. Despite these major advances, a better molecular and cellular characterization of the tumor microenvironment is still needed because it has a crucial role in the development and progression of HCC. Inflamed (hot) and noninflamed (cold) HCC tumors and genomic signatures have been associated with response to ICIs. However, there are no additional biomarkers to guide clinical decision‐making. Other immune‐targeting strategies, such as adoptive T‐cell transfer, vaccination, and virotherapy, are currently under development. This review provides an overview on the HCC immune microenvironment, different cellular players, current available immunotherapies, and potential immunotherapy modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–233 of 233
Teng, C., Wang, T., Wu, T., Lin, J., Shih, F., Shyu, W., & Jeng, L. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922034 · Cited by 60
HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers
Zhang, H., Feng, Q., Chen, W., & Wang, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113295 · Cited by 57
Pathologic and molecular features of hepatocellular carcinoma: An update
Vij, M., & Caldéraro, J. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i4.393 · Cited by 56
Kalathil, S. G., & Thanavala, Y. M. (2021) · Cells · doi:10.3390/cells10061332 · Cited by 56
Immune control and failure in HCV infection—tipping the balance
Dustin, L. B., Cashman, S. B., & Laidlaw, S. M. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0214-126r · Cited by 53
Docta, R. Y., Ferronha, T., Sanderson, J. P., et al. (2018) · Hepatology · doi:10.1002/hep.30477 · Cited by 53
Natural Killer–Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy
Cazzetta, V., Franzese, S., Carenza, C., Bella, S. D., Mikulak, J., & Mavilio, D. (2021) · Cancers · doi:10.3390/cancers13092184 · Cited by 50
González‐Carmona, M. A., Märten, A., Hoffmann, P., Schneider, C., Sievers, E., Schmidt‐Wolf, I. G. H., Sauerbruch, T., & Caselmann, W. H. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01235.x · Cited by 47
Chen, C., MA, Y.-H., Zhang, Y., Zhang, F., Zhou, N., Wang, X., LIU, T., & Li, Y. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.06.002 · Cited by 47
Meng, Y.-M., Liang, J., Wu, C., Xu, J., Zeng, D.-N., Yu, X.-J., Ning, H., Xu, L., & Zheng, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408745 · Cited by 42
Identification of serum CCL15 in hepatocellular carcinoma
Li, Y., Wu, J., Zhang, W., Zhang, N., & Guo, H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.494 · Cited by 40
Zhang, Q., Jia, Q., Wang, H., Hu, C.-X., Sun, D., Jiang, R.-D., & Zhang, Z. (2016) · BMC Cancer · doi:10.1186/s12885-016-2883-z · Cited by 40
Yu, M., & Li, Z. (2017) · Frontiers of Medicine · doi:10.1007/s11684-017-0546-3 · Cited by 39
Zhou, D., Qin, J., Huang, J., Wang, F., Xu, G., Lv, Y., Zhang, J., & Shen, L.-M. (2017) · Oncology Letters · doi:10.3892/ol.2017.6717 · Cited by 39
Yasuoka, H., Asai, A., Ohama, H., Tsuchimoto, Y., Fukunishi, S., & Higuchi, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-67497-2 · Cited by 39
T Cells Doing It for Themselves: TGF-β Regulation of Th1 and Th17 Cells
McGeachy, M. J., & Cua, D. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.003 · Cited by 38
Brunner, S. M., Itzel, T., Rubner, C., Kesselring, R., Griesshammer, E., Evert, M., Teufel, A., Schlitt, H. J., & Fichtner‐Feigl, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20238 · Cited by 38
Ahlén, G., Derk, E., Weiland, M., et al. (2008) · Gut · doi:10.1136/gut.2007.147264 · Cited by 34
Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma
Qin, M., Wang, D., Fang, Y., Zheng, Z., Liu, X., Wu, F., Wang, L., Li, X., Hui, B., Ma, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.647854 · Cited by 34
Hu, W., Huang, X., Huang, X., Chen, W., Hao, L.-D., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109333 · Cited by 29
Teng, C., Wang, T., Shih, F., Shyu, W., & Jeng, L. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15398 · Cited by 29
Chu, H. H., Kim, J. H., Shim, J. H., Gwon, D. I., Ko, H.-K., Shin, J. H., Ko, G., Yoon, H., & Kim, N. (2021) · Cancers · doi:10.3390/cancers13112830 · Cited by 29
Kitahara, M., Mizukoshi, E., Terashima, T., Nakagawa, H., Horii, R., Iida, N., Arai, K., Yamashita, T., Sakai, Y., Yamashita, T., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100777 · Cited by 28
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma
Zecca, A., Barili, V., Canetti, D., Regina, V., Olivani, A., Carone, C., Capizzuto, V., Zerbato, B., Trenti, T., Valle, R. D., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02561-4 · Cited by 27
Distribution of HLA haplotypes across Japanese Archipelago: similarity, difference and admixture
Nakaoka, H., & Inoue, I. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.90 · Cited by 26
Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
Lee, B. M., & Seong, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i10.919 · Cited by 24
He, Y., Yuan, H., & Mizejewski, G. J. (2014) · Immunotherapy · doi:10.2217/imt.14.46 · Cited by 21
Vogt, A., Sadeghlar, F., Ayub, T. H., Schneider, C., Möhring, C., Zhou, T., Mahn, R., Bartels, A., Praktiknjo, M., Kornek, M., et al. (2021) · Cancers · doi:10.3390/cancers13133375 · Cited by 21
Li, Z., Gong, H., Liu, Q., Wu, W., Cheng, J., Mei, Y., Chen, Y., Zheng, H., Yu, X., Zhong, S., et al. (2019) · Immunology · doi:10.1111/imm.13168 · Cited by 20
Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma.
Yang, J. Y., Eresen, A., Scotti, A., Cai, K., & Zhang, Z. (2021) · American Journal of Cancer Research · Cited by 20
Zhang, Z., Zhu, Y., Xu, D., Li, T., Li, J., Xiao, Z.-T., Chen, M., Yang, X. L., Jia, H., Dong, Q., et al. (2021) · Europe PMC (PubMed Central) · Cited by 13
Lei, C., Liu, J., Wu, R., Long, Z., Zhang, J.-Z., Tao, D., & Liu, Y.-P. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.04.019 · Cited by 12
Asai, A., Yasuoka, H., Matsui, M., Tsuchimoto, Y., Fukunishi, S., & Higuchi, K. (2020) · Cancers · doi:10.3390/cancers12082286 · Cited by 7
Cited by
Constructing biomimetic microenvironments for liver regeneration
(2025) · doi:10.1186/s12951-025-03729-9 · Cited by 11
Metadata
- Authors
- Donne, R., & Lujambio, A.
- Venue
- Hepatology
- Published
- 2023-04-17
- Volume
- 77
- Issue
- 5
- Pages
- 1773-1796
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4292553490
- Cited by
- 631
- References
- 233
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.